Navigation Links
EMK Placental Appoints Beauty Beverly Hills for Exclusive Distributorship.
Date:3/24/2009

BEVERLY HILLS, Calif., March 24 /PRNewswire/ -- Regal International, Inc., doing business as Beauty Beverly Hills (www.beautybeverlyhills.com) has been appointed by EMK Products, LLC to be the exclusive distributor of the EMK PLACENTAL(R) Skin Care Product line. Under the agreement, Beauty Beverly Hills will be allotted exclusive worldwide distributorship for the development and management of internet affiliates, marketing and sales.

Beauty Beverly Hills will be working to boost market share of the EMK product line by rapidly increasing market penetration based on a detailed market segmentation analysis it has conducted. Furthermore, Beauty Beverly Hills will be instrumental in implementing market expansion strategies to boost its affiliate network of partners. Beauty Beverly Hills has enlisted the services of Linkshare (www.linkshare.com) the largest network affiliate partners of any program provider, as a means to expand its affiliate network and create a shared revenue generation model with prospective affiliates.

"Beauty Beverly Hills has assembled a powerful team of business professionals with an extensive track record in IT consulting, marketing and public relations," says Benik Hovsepian, President of Beauty Beverly Hills. "We are excited to bring out the market potential of an already popular product used by many of the world's most well known celebrities."

Current industry trends report that the skincare industry has seen significant consecutive growth in non-invasive skin care treatment and anti-aging facial products. The cosmetic industry as a whole saw a 4 to 7 percent annual growth during 2003-2007 and will be worth $21 billion by 2012, claims Packaged Facts, a leading publisher of market research. It forecasts that anti-aging facial skincare products will continue to be the faste
'/>"/>

SOURCE Beauty Beverly Hills
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Fujirebio Diagnostics Appoints Grady Barnes as Chief Scientific Officer
2. TrinityCare Appoints Kirk B. Shulke, M.D. to Board of Directors
3. Telecare Corporation Appoints Pat Doyle Vice President of Sales and Hospital Contracting
4. Kenya Government Appoints Emergency Health Workers to Permanent Positions
5. TrinityCare Appoints Decorated Christian Artist Al Denson to Board of Directors
6. Cord Blood America, Inc. Appoints Somerville Associates, Public Relations Counsel
7. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
8. NeoGenomics Appoints Douglas M. VanOort as Executive Chairman and Interim Chief Executive Officer
9. Care Investment Trust Inc. Announces Quarterly Dividend - Appoints Paul F. Hughes CFO and Treasurer
10. Velos, Inc. Appoints William Broucek Senior Director, Professional Services
11. RoundTable Appoints Senior Healthcare Executives
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 4Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 5Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 6Health News:Wellness Manufacturer Wins Two 2009 American Spa Awards 2Health News:NVHR Offers Congressman Hank Johnson Support & Encouragement as He Battles Chronic Hepatitis C Virus 2Health News:Americans United for Life Action Fights the Abortion Bailout by Supporting the Nelson-Hatch-Casey Amendment 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 3
Breaking Medicine Technology:FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Baxa IntelliFlowRx 28TM 29 Upgrades Expand Pharmacy Capabilities 57968 1Baxa IntelliFlowRx 28TM 29 Upgrades Expand Pharmacy Capabilities 57968 2Baxa IntelliFlowRx 28TM 29 Upgrades Expand Pharmacy Capabilities 57968 3Oracle OpenWorld 2009 Panel to Feature Two Experts from National Healthcare Leadership Organizations the FDA and GS1 Healthcare US with Loftware 57966 1Oracle OpenWorld 2009 Panel to Feature Two Experts from National Healthcare Leadership Organizations the FDA and GS1 Healthcare US with Loftware 57966 2Oracle OpenWorld 2009 Panel to Feature Two Experts from National Healthcare Leadership Organizations the FDA and GS1 Healthcare US with Loftware 57966 3National Council on Disability to Recommend Health Care Changes for People With Disabilities 57964 1
Other Medicine Technology:Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 2Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 3Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 4Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 5Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 6Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 7Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 8Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 9Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 10Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 11Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 12Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System 2Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System 3Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System 4